This is a non-interventional, cross-sectional, qualitative study in which patients diagnosed with MS and clinicians with experience treating MS will be interviewed regarding patient experiences with the wearing off effect from ocrelizumab, natalizumab, and ofatumumab
Study Type
OBSERVATIONAL
Enrollment
39
Non-interventional, cross-sectional, qualitative study. There is no treatment allocation. Patients prescribed with Disease-modifying therapy in the commercial setting are eligible to enroll into this study.
Non-interventional, cross-sectional, qualitative study. There is no treatment allocation. Patients prescribed with Disease-modifying therapy in the commercial setting are eligible to enroll into this study.
Non-interventional, cross-sectional, qualitative study. There is no treatment allocation. Patients prescribed with Disease-modifying therapy in the commercial setting are eligible to enroll into this study.
Novartis Investigative Site
Basel, Switzerland
Number of participants with key symptoms associated with the wearing off effect
Number of participants with the following recurring symptoms will be collected: * Fatigue * Physical Pain * Mobility issues or walking difficulties * Numbness or sensory issues * Cognitive difficulties * Weakness * Spasms * Balance disturbance or dizziness * Blurry vision or visual impairment * Others
Time frame: Assessed at the time of interview with lookback period from time of first MS diagnosis, up to 3 months
Severity of wearing off effect symptoms
Based on qualitative score rating
Time frame: Assessed at the time of interview with lookback period from time of first MS diagnosis, up to 3 months
Detailed language used to describe the experience of wearing off effect
Terms used to describe times when patients MS "gets better" and when it "gets worse" will be collected.
Time frame: Assessed at the time of interview with lookback period from time of first MS diagnosis, up to 3 months
Number of participants switching from one therapy to another due to wearing off effect
Number of participants switching from one therapy to another due to wearing off effect will be collected
Time frame: Assessed at the time of interview with lookback period from time of first MS diagnosis, up to 3 months
Number of participants who changed the dosing/infusion schedules due to wearing off effect
Number of participants who changed the dosing/infusion schedules due to wearing off effect will be collected
Time frame: Assessed at the time of interview with lookback period from time of first MS diagnosis, up to 3 months
Dissimilarities of clinician' and patients' views of wearing off effect
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Assessed qualitatively via concept coding techniques
Time frame: Assessed at the time of interview with lookback period from time of first MS diagnosis, up to 3 months